Pfizer's Lipitor Patent Invalidated In South Korea

Law360 (June 26, 2008, 12:00 AM EDT) -- A South Korean court has reportedly ruled against Pfizer Inc. in a patent suit over the blockbuster cholesterol-reducing drug Lipitor.

A South Korean court on Thursday upheld an earlier ruling that Pfizer's Lipitor patent was invalid and that the generic made by five South Korean pharmaceutical companies did not breach the patent, Reuters reported.

Korean drug companies producing the generic include Dong-A Pharmaceutical and Boryung Pharmaceutical.

Pfizer plans to appeal the ruling in the Korean Supreme Court.

“We are hopeful that a higher court will reverse...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.